Skip to main content

Table 3 Factors associated with TTP during the first two months of treatment

From: Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study

Variable

Unadjusted

Adjusted

IRR (95% CI)

P-value

IRR (95% CI)

P-value

Baseline CT valuea

 Week 0

1.02 (1.02  ̶ 1.03)

<  0.001

1.05 (1.04  ̶ 1.06)

<  0.001

 Week 2

1.04 (1.03  ̶ 1.04)

<  0.001

1.03 (1.02  ̶ 1.04)

<  0.001

 Week 4

1.03 (1.02  ̶ 1.03)

<  0.001

1.02 (1.01  ̶ 1.03)

<  0.001

 Week 6

1.01 (1.00  ̶ 1.02)

    0.009

1.00 (0.99  ̶ 1.01)

    0.376

 Week 8

1.01 (1.00  ̶ 1.01)

    0.001

1.00 (0.99  ̶ 1.01)

    0.296

CD4 cell count

  ≤ 200 cells/μL

Ref

   

 > 200 cells/μL

1.10 (1.06  ̶ 1.14)

<  0.001

1.05 (1.00  ̶ 1.09)

    0.034

Cavitation

 No

Ref

   

 Yes

0.75 (0.72–0.79)

<  0.001

0.83 (0.79  ̶ 0.88)

<  0.001

ART status

 On ART

Ref

   

 Not on ART

1.07 (1.03  ̶ 1.12)

   0.001

1.03 (1.00  ̶ 1.06)

   0.098

BMI

  ≤ 18.5

Ref

   

 > 18.5

0.93 (0.89  ̶ 0.97)

<  0.001

0.72 (0.56  ̶ 1.10)

   0.067

Sex

 Male

Ref

   

 Female

0.99 (0.95  ̶ 1.03)

    0.596

  

Age

1.00 (0.99  ̶ 1.00)

    0.444

  
  1. aEffect of baseline CT value on change in TTP at weeks 2, 4, 6 and 8 with reference to the baseline TTP